Strides Shasun Limited has received approval from the United States Food & Drug Administration (FDA) for polyethylene glycol 3350, powder for solution 17 grams/capful and 17 grams/packet (OTC).
 
According to Nielsen data, the US market for polyethylene glycol 3350, powder for solution (OTC) is approximately US$ 260 million. The product will be manufactured at company’s flagship plant at Bengaluru and will be marketed by Strides Pharma Inc in the US market. The product will be launched in Q4 FY 2017, in line with the OTC procurement cycle in the market.
 
Polyethylene glycol-3350 powder for oral solution is anosmotic laxative that relieves occasional constipation. It works by softening the stool and increasing the frequency of bowel movements by retaining water in the stool.